Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers - Oncodaily
Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers Oncodaily
Non-Hodgkin Lymphoma News
Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress
Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress
ST-001 nanoFenretinide Shows Antitumor Activity in Previously Treated Cutaneous T-Cell Lymphoma - OncLive
ST-001 nanoFenretinide Shows Antitumor Activity in Previously Treated Cutaneous T-Cell Lymphoma OncLive
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights
U.S. Supreme Court Blocks Roundup Lawsuits Over Non-Hodgkin’s Lymphoma Warnings - AboutLawsuits.com
U.S. Supreme Court Blocks Roundup Lawsuits Over Non-Hodgkin’s Lymphoma Warnings AboutLawsuits.com
A Rare Case of Non-Hodgkin Lymphoma of the Tracheobronchial Tree - Cureus
A Rare Case of Non-Hodgkin Lymphoma of the Tracheobronchial Tree Cureus
Non-Hodgkin lymphoma survivor thankful for clinical trial - UT MD Anderson
Non-Hodgkin lymphoma survivor thankful for clinical trial UT MD Anderson
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers
New long-term analysis suggests follicular lymphoma can be cured - Fred Hutchinson Cancer Center
New long-term analysis suggests follicular lymphoma can be cured Fred Hutchinson Cancer Center
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma - Targeted Oncology
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma Targeted Oncology
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma - CancerNetwork
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma CancerNetwork
Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - Wiley
Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Wiley
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete - Nature
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete Nature
Miami F Marcus Allen has non-Hodgkin lymphoma, out for season - ESPN
Miami F Marcus Allen has non-Hodgkin lymphoma, out for season ESPN
Advances in lymphoma treatment therapies and clinical trials - Penn Medicine
Advances in lymphoma treatment therapies and clinical trials Penn Medicine
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma - CancerNetwork
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma CancerNetwork
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin - UT MD Anderson
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin UT MD Anderson
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies - Frontiers
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers
Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report - Frontiers
Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report Frontiers
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes - GlobeNewswire
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes GlobeNewswire
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] - robertkinglawfirm.com
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] robertkinglawfirm.com
Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial - Nature
Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial Nature
Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges - Cureus
Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges Cureus
Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report - Frontiers
Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report Frontiers
Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy - Cureus
Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy Cureus
Andy Whitfield’s Final Battle: The Spartacus Star and Stage IV Non-Hodgkin Lymphoma - Oncodaily
Andy Whitfield’s Final Battle: The Spartacus Star and Stage IV Non-Hodgkin Lymphoma Oncodaily
Legend Biotech Announces Late-Breaking Oral Presentation at - GlobeNewswire
Legend Biotech Announces Late-Breaking Oral Presentation at GlobeNewswire
Current treatment algorithm: diffuse large B cell lymphoma - Nature
Current treatment algorithm: diffuse large B cell lymphoma Nature
What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits? - Reuters
What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits? Reuters
Non-Hodgkin lymphoma: inpatient TLS is uncommon but predictable from high–tumor burden and early lab derangements - Vera Health
Non-Hodgkin lymphoma: inpatient TLS is uncommon but predictable from high–tumor burden and early lab derangements Vera Health
CAR-NK Shows Long-Term Response in Waldenström Non-Hodgkin Lymphoma - Cure Today
CAR-NK Shows Long-Term Response in Waldenström Non-Hodgkin Lymphoma Cure Today
Genmab lymphoma trial cuts progression risk 60% in phase 3 study - Stock Titan
Genmab lymphoma trial cuts progression risk 60% in phase 3 study Stock Titan
Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription - Nature
Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription Nature
New Diagnosis of B-cell Follicular Lymphoma Temporally Associated With Routine Vaccination: A Report of Two Cases - Cureus
New Diagnosis of B-cell Follicular Lymphoma Temporally Associated With Routine Vaccination: A Report of Two Cases Cureus
Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation - Frontiers
Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation Frontiers
T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma - Targeted Oncology
T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma Targeted Oncology
Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma - The ASCO Post
Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma The ASCO Post
Non-Hodgkin lymphoma survival rate: Outlook and more - Medical News Today
Non-Hodgkin lymphoma survival rate: Outlook and more Medical News Today
Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature - Frontiers
Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature Frontiers